<?xml version="1.0" encoding="UTF-8" ?>
<modsCollection xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" xmlns:slims="http://senayan.diknas.go.id" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
<mods version="3.3" ID="1623">
<titleInfo>
<title>Marmara Pharmaceutical Journal of Research in Pharmacy Journal of Research in Pharmacy 2020 , Vol 24 Issue 5</title>
</titleInfo>
<typeOfResource manuscript="yes" collection="yes">mixed material</typeOfResource>
<genre authority="marcgt">bibliography</genre>
<originInfo>
<place><placeTerm type="text"></placeTerm></place>
<publisher></publisher>
<dateIssued></dateIssued>
<issuance>monographic</issuance>
<edition>Vol 24 Issue 5</edition>
</originInfo>
<language>
<languageTerm type="code">id</languageTerm>
<languageTerm type="text">Indonesia</languageTerm>
</language>
<physicalDescription>
<form authority="gmd">Karya Tulis Ilmiah</form>
<extent></extent>
</physicalDescription>
<note>ABSTRACT: Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) which is the human coronavirus and a
member of the Coronaviridae family leads to fatal pneumonia cases. Severe acute respiratory syndrome corona virus 2
attaches to the cells in the human body through binding to the angiotensin converting enzyme 2 (ACE2) receptor with
the spike (S) protein. Firstly, SARS-CoV-2 arised in China in late 2019 and was reported to the World Health
Organization (WHO). The World Health Organization named the disease caused by this virus as corona virus disease
(COVID)-19. SARS-CoV-2 which has human-to-human transmission through droplets, direct contact and aerosol routes

have affected more than 10 million people and caused more than 500 thousand deaths. Clinical symptoms of COVID-
19 are fever, dry cough, sore throat, respiratory distress, lung damage, and diarrhea. In severe cases, mechanical

ventilation is required and multiple organ damage is encountered. COVID-19 is diagnosed with real-time polymerase
chain reaction (PCR) technique which is applied to saliva and swab samples taken from the nose or nasal cavity. Lung
damage is detected by computerized tomography (CT). COVID-19 develops more severely in patients with
comorbidities such as hypertension, diabetes and cancer. While vaccine and drug development studies are continuing

all over the world, available antiviral drugs such as umifenovir, remdesivir, favipiravir are also tested against SARS-
CoV-2. Moreover, the plasma donated from the recovered patients are tested for COVID-19 treatment. Additionally,

treating the inflammatory conditions developing due to COVID-19 and applying antimicrobial drugs against co-
infections are among the current approaches.

KEYWORDS: SARS-CoV-2; COVID-19; COVID-19 comorbidities; COVID-19 treatment.</note>
<classification></classification><identifier type="isbn"></identifier><location>
<physicalLocation>PERPUSTAKAAN SEKOLAH TINGGI ILMU KESEHATAN SAMARINDA REPOSITORY</physicalLocation>
<shelfLocator></shelfLocator>
<holdingSimple>
<copyInformation>
<numerationAndChronology type="1">JIN0087</numerationAndChronology>
<sublocation>Perpus.Akfarsam (jurnal Internasioan)</sublocation>
<shelfLocator>615 MAR b</shelfLocator>
</copyInformation>
</holdingSimple>
</location>
<slims:digitals>
<slims:digital_item id="1698" url="https://drive.google.com/file/d/14ep7MLh7wQwdd2JBg_TRCSBm4RIn9KJ6/view?usp=sharing" path="/https://drive.google.com/file/d/14ep7MLh7wQwdd2JBg_TRCSBm4RIn9KJ6/view?usp=sharing" mimetype="text/uri-list">Marmara Pharmaceutical Journal of Research in Pharmacy Journal of Research in Pharmacy 2020 , Vol 24 Issue 5</slims:digital_item>
</slims:digitals><recordInfo>
<recordIdentifier>1623</recordIdentifier>
<recordCreationDate encoding="w3cdtf">2022-07-20 10:42:53</recordCreationDate>
<recordChangeDate encoding="w3cdtf">2022-07-20 10:55:38</recordChangeDate>
<recordOrigin>machine generated</recordOrigin>
</recordInfo></mods></modsCollection>